Cantor Fitzgerald raised the firm’s price target on Supernus (SUPN) to $63 from $46 and keeps an Overweight rating on the shares. The firm updated its model for ONAPGO to factor in a faster cadence of patients on therapy that slightly increases its peak sales potential. Cantor believes there may be even more upside beyond its ONAPGO estimates at this time, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SUPN:
- Supernus price target raised to $40 from $36 at Piper Sandler
- Supernus Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges
- Supernus Pharmaceuticals Reports Strong Q2 2025 Results
- Supernus reports Q2 EPS 40c vs. 36c last year
- Supernus raises FY25 revenue view $670M-$700M from $600M-$630M